BASILEAPHARMA.US

Basilea Pharmaceutica - Home

Mr Hans-Beat Gürtler. Dr Thomas M. Rinderknecht. Mr Steven D. Skolsky. Transparence des liens d’intérêt. How to find us. Investor Relations / Media. Rsaquo;› go! Go to Annual report 2014. Link to Share Information. Monday, May 04. 2015. Basilea reports start of first-in-human phase 1 oncology study with oral panRAF kinase inhibitor. Wednesday, April 29. 2015. Basilea shareholders approve all resolutions proposed by the Board of Directors at the Ordinary General Meeting of Shareholders. Basel, Switzerland...

http://www.basileapharma.us/

OVERVIEW OF basileapharma.us

TRAFFIC RANK

>1,000,000

REVIEWS

0

PAGES IN THIS WEBSITE

0

LINKS TO THIS WEBSITE

CONTACTS

ADDRESSES

SOCIAL LINKS

ONLINE SINCE

WEBSITE DETAILS

SEO

PAGES

SIMILAR SITES

TRAFFIC RANK FOR BASILEAPHARMA.US

TODAY'S RATING

>1,000,000

TRAFFIC RANK - AVERAGE PER MONTH

BEST MONTH

July

AVERAGE PER DAY Of THE WEEK

HIGHEST TRAFFIC ON

Saturday

TRAFFIC BY CITY

Sign up

CUSTOMER REVIEWS

Average Rating: 4.1 out of 5 with 9 reviews

5 star

3

4 star

4

3 star

2

2 star

0

1 star

0

Hey there! Start your review of basileapharma.us

AVERAGE USER RATING

Write a Review

WEBSITE PREVIEW

LOAD TIME

CONTACTS AT BASILEAPHARMA.US

Basilea Pharmaceutica Ltd

Roland Weiss

Grenzac●●●●●●●sse 487

Ba●●el , BS, 4058

Switzerland CH

41.6●●●●1111

41.6●●●●1112

ro●●●●●●●●●●@basileapharma.com

View this contact

Basilea Pharmaceutica Ltd

Domain Admin

Grenzac●●●●●●●sse 487

Ba●●el , Basel, 4005

UNITED KINGDOM GB

41.6●●●●1111

41.6●●●●1112

do●●●●●●●●●@basileapharma.com

View this contact

NetBenefit d/b/a/ Netnames Ltd

NetNames Billing

11 Cler●●●●●●●l Green

Lo●●on , EC1R 0DP

United Kingdom UK

44.2●●●●5355

44.2●●●●5366

bi●●●●●@netnames.com

View this contact

Netnames

Netnames Hostmaster

10-11 Cl●●●●●●●●ll Green

Lo●●on , EC1R 0DP

UNITED KINGDOM GB

44.2●●●●5355

44.2●●●●5366

ho●●●●●●●●@netnames.com

View this contact

ADD CONTACT

Login

TO VIEW CONTACTS

Remove Contacts

FOR PRIVACY ISSUES

DOMAIN REGISTRATION INFORMATION

REGISTERED: n/a
UPDATED: n/a
EXPIRATION: n/a

BUY YOUR DOMAIN

NAME SERVERS

1: ns3.netnames.net
2: ns4.netnames.net

REGISTRAR

ASCIO TECHNOLOGIES, INC. DANMARK – FILIAL AF ASCIO TECHNOLOGIES, INC. USA NETBENEFIT D/B/A NETNAMES BATCHCSR

WHOIS : whois.nic.us

REFERRED :

CONTENT

PAGES IN
THIS WEBSITE

0

SSL

EXTERNAL LINKS

0

SITE IP

52.210.26.87

LOAD TIME

0 sec

SCORE

6.2

PAGE TITLE

Basilea Pharmaceutica - Home | basileapharma.us Reviews

<META> DESCRIPTION

Mr Hans-Beat Gürtler. Dr Thomas M. Rinderknecht. Mr Steven D. Skolsky. Transparence des liens d’intérêt. How to find us. Investor Relations / Media. Rsaquo;› go! Go to Annual report 2014. Link to Share Information. Monday, May 04. 2015. Basilea reports start of first-in-human phase 1 oncology study with oral panRAF kinase inhibitor. Wednesday, April 29. 2015. Basilea shareholders approve all resolutions proposed by the Board of Directors at the Ordinary General Meeting of Shareholders. Basel, Switzerland...

<META> KEYWORDS

1 biotechnology company

2 discovery

3 development

4 novel drugs

5 unmet medical needs

6 anti-bacterials

7 anti-fungals

8 dermatology

9

10 coupons

CONTENT

Page content here

KEYWORDS ON PAGE

site map,quick links,e mail distribution,ad hoc notices,financial reports,corporate calendar,corporate,corporate information,board of directors,dr martin nicklasson,mr domenico scala,prof daniel lew,dr thomas werner,board committees,management committee

SERVER

Apache

POWERED BY

PHP/5.5.9-1ubuntu4.17

CONTENT-TYPE

utf-8

GOOGLE PREVIEW

Basilea Pharmaceutica - Home | basileapharma.us Reviews

https://basileapharma.us

Mr Hans-Beat Gürtler. Dr Thomas M. Rinderknecht. Mr Steven D. Skolsky. Transparence des liens d’intérêt. How to find us. Investor Relations / Media. Rsaquo;› go! Go to Annual report 2014. Link to Share Information. Monday, May 04. 2015. Basilea reports start of first-in-human phase 1 oncology study with oral panRAF kinase inhibitor. Wednesday, April 29. 2015. Basilea shareholders approve all resolutions proposed by the Board of Directors at the Ordinary General Meeting of Shareholders. Basel, Switzerland...

OTHER SITES

basileapharma.biz

Basilea Pharmaceutica - Home

Mr Hans-Beat Gürtler. Dr Thomas M. Rinderknecht. Mr Steven D. Skolsky. Transparence des liens d’intérêt. How to find us. Investor Relations / Media. Rsaquo;› go! Go to Annual report 2014. Link to Share Information. Monday, May 04. 2015. Basilea reports start of first-in-human phase 1 oncology study with oral panRAF kinase inhibitor. Wednesday, April 29. 2015. Basilea shareholders approve all resolutions proposed by the Board of Directors at the Ordinary General Meeting of Shareholders. Basel, Switzerland...

basileapharma.com

Basilea Pharmaceutica - Home

Mr Hans-Beat Gürtler. Dr Thomas M. Rinderknecht. Mr Steven D. Skolsky. Transparence des liens d’intérêt. How to find us. Investor Relations / Media. Rsaquo;› go! Go to Annual report 2014. Link to Share Information. Monday, May 04. 2015. Basilea reports start of first-in-human phase 1 oncology study with oral panRAF kinase inhibitor. Wednesday, April 29. 2015. Basilea shareholders approve all resolutions proposed by the Board of Directors at the Ordinary General Meeting of Shareholders. Basel, Switzerland...

basileapharma.info

Basilea Pharmaceutica - Home

Mr Hans-Beat Gürtler. Dr Thomas M. Rinderknecht. Mr Steven D. Skolsky. Transparence des liens d’intérêt. How to find us. Investor Relations / Media. Rsaquo;› go! Go to Annual report 2014. Link to Share Information. Monday, May 04. 2015. Basilea reports start of first-in-human phase 1 oncology study with oral panRAF kinase inhibitor. Wednesday, April 29. 2015. Basilea shareholders approve all resolutions proposed by the Board of Directors at the Ordinary General Meeting of Shareholders. Basel, Switzerland...

basileapharma.net

Basilea Pharmaceutica - Home

Mr Hans-Beat Gürtler. Dr Thomas M. Rinderknecht. Mr Steven D. Skolsky. Transparence des liens d’intérêt. How to find us. Investor Relations / Media. Rsaquo;› go! Go to Annual report 2014. Link to Share Information. Monday, May 04. 2015. Basilea reports start of first-in-human phase 1 oncology study with oral panRAF kinase inhibitor. Wednesday, April 29. 2015. Basilea shareholders approve all resolutions proposed by the Board of Directors at the Ordinary General Meeting of Shareholders. Basel, Switzerland...

basileapharma.org

Basilea Pharmaceutica - Home

Mr Hans-Beat Gürtler. Dr Thomas M. Rinderknecht. Mr Steven D. Skolsky. Transparence des liens d’intérêt. How to find us. Investor Relations / Media. Rsaquo;› go! Go to Annual report 2014. Link to Share Information. Monday, May 04. 2015. Basilea reports start of first-in-human phase 1 oncology study with oral panRAF kinase inhibitor. Wednesday, April 29. 2015. Basilea shareholders approve all resolutions proposed by the Board of Directors at the Ordinary General Meeting of Shareholders. Basel, Switzerland...

basileapharma.us

Basilea Pharmaceutica - Home

Mr Hans-Beat Gürtler. Dr Thomas M. Rinderknecht. Mr Steven D. Skolsky. Transparence des liens d’intérêt. How to find us. Investor Relations / Media. Rsaquo;› go! Go to Annual report 2014. Link to Share Information. Monday, May 04. 2015. Basilea reports start of first-in-human phase 1 oncology study with oral panRAF kinase inhibitor. Wednesday, April 29. 2015. Basilea shareholders approve all resolutions proposed by the Board of Directors at the Ordinary General Meeting of Shareholders. Basel, Switzerland...

basileapharmaceutica.biz

Basilea Pharmaceutica - Home

Mr Hans-Beat Gürtler. Dr Thomas M. Rinderknecht. Mr Steven D. Skolsky. Transparence des liens d’intérêt. How to find us. Investor Relations / Media. Rsaquo;› go! Go to Annual report 2014. Link to Share Information. Monday, May 04. 2015. Basilea reports start of first-in-human phase 1 oncology study with oral panRAF kinase inhibitor. Wednesday, April 29. 2015. Basilea shareholders approve all resolutions proposed by the Board of Directors at the Ordinary General Meeting of Shareholders. Basel, Switzerland...

basileapharmaceutica.ch

Basilea Pharmaceutica - Home

Mr Hans-Beat Gürtler. Dr Thomas M. Rinderknecht. Mr Steven D. Skolsky. Transparence des liens d’intérêt. How to find us. Investor Relations / Media. Rsaquo;› go! Go to Annual report 2014. Link to Share Information. Monday, May 04. 2015. Basilea reports start of first-in-human phase 1 oncology study with oral panRAF kinase inhibitor. Wednesday, April 29. 2015. Basilea shareholders approve all resolutions proposed by the Board of Directors at the Ordinary General Meeting of Shareholders. Basel, Switzerland...

basileapharmaceutica.com

Basilea Pharmaceutica - Home

Mr Hans-Beat Gürtler. Dr Thomas M. Rinderknecht. Mr Steven D. Skolsky. Transparence des liens d’intérêt. How to find us. Investor Relations / Media. Rsaquo;› go! Go to Annual report 2014. Link to Share Information. Monday, May 04. 2015. Basilea reports start of first-in-human phase 1 oncology study with oral panRAF kinase inhibitor. Wednesday, April 29. 2015. Basilea shareholders approve all resolutions proposed by the Board of Directors at the Ordinary General Meeting of Shareholders. Basel, Switzerland...

basileapharmaceutica.info

Basilea Pharmaceutica - Home

Mr Hans-Beat Gürtler. Dr Thomas M. Rinderknecht. Mr Steven D. Skolsky. Transparence des liens d’intérêt. How to find us. Investor Relations / Media. Rsaquo;› go! Go to Annual report 2014. Link to Share Information. Monday, May 04. 2015. Basilea reports start of first-in-human phase 1 oncology study with oral panRAF kinase inhibitor. Wednesday, April 29. 2015. Basilea shareholders approve all resolutions proposed by the Board of Directors at the Ordinary General Meeting of Shareholders. Basel, Switzerland...

basileapharmaceutica.net

Basilea Pharmaceutica - Home

Mr Hans-Beat Gürtler. Dr Thomas M. Rinderknecht. Mr Steven D. Skolsky. Transparence des liens d’intérêt. How to find us. Investor Relations / Media. Rsaquo;› go! Go to Annual report 2014. Link to Share Information. Monday, May 04. 2015. Basilea reports start of first-in-human phase 1 oncology study with oral panRAF kinase inhibitor. Wednesday, April 29. 2015. Basilea shareholders approve all resolutions proposed by the Board of Directors at the Ordinary General Meeting of Shareholders. Basel, Switzerland...